New obesity drug REGN20934 enters first human safety trial
NCT ID NCT07594093
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 study tests a new drug called REGN20934 in 90 adults who are overweight or obese. The main goal is to check the drug's safety, side effects, and how the body processes it. Participants receive a single dose of either the drug or a placebo, and researchers monitor them closely. This is an early step to see if the drug is safe enough for further testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN20934
What this could lead to
If successful, this early study could pave the way for a new weight management drug.
What could go wrong
This is a very early Phase 1 trial focused on safety, not weight loss. It involves only 90 people and may not lead to an effective treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••